NCT00079404View on ClinicalTrials.gov

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

May 31, 2006

Conditions
Acute Undifferentiated LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

tanespimycin

Given IV

Trial Locations (1)

91006-3776

COG Phase I Consortium, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00079404 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | Biotech Hunter | Biotech Hunter